Board of Directors

Jim Buck

President & CEO
Jim Buck joined Mardil Medical in September, 2010 after more than nineteen years of experience successfully developing and commercializing innovative medical technologies. Prior to joining Mardil, Jim served as President & CEO of SetPoint Medical, a privately funded early stage developer of an implantable neuromodulation device system to regulate uncontrolled inflammation; VP, marketing & business development at InnerPulse, a privately funded developer of a novel implantable defibrillator system; and VP, marketing & business development at Closure Medical, leading the product mapping strategy and execution for a breakthrough surgical sealant and adhesive technology culminating in a $370 million acquisition and integration into Johnson & Johnson.

Previous to Closure Medical/J&J, Jim held several positions of increasingly greater responsibility over eleven years at cardiac medical device leader St. Jude Medical. Jim holds a master of management from Northwestern University’s Kellogg Graduate School of management and a bachelor’s degree from Indiana University. Jim resides with his wife Lisa and four children in Orono, MN.


Marshall S. Stanton, MD

StantonDr. Stanton joined Mardil’s Board in 2012 and is Vice President and General Manager of the Implantable Defibrillator business within Medtronic’s Cardiac Rhythm Disease Management (CRDM) business. Marshall has over 25 years of experience in cardiac rhythm management including 15 years at Medtronic and 10 years as a staff cardiologist at Mayo Clinic.

Prior to his current role, Dr. Stanton was Vice President for Clinical Research for Medtronic’s Cardiac and Vascular Group of businesses. Recently, Dr. Stanton was Vice President and General Manager for the Medtronic Japan CRDM business from May 2005 through June 2007 where he had responsibility for all aspects of the CRDM and PhysioControl businesses in Japan. Dr. Stanton had been the Medical Director for the CRDM business since joining Medtronic in 1998 until 2005. In this position, Dr. Stanton focused on the electrophysiology market worldwide, bringing healthcare expertise to product plans, quality, and education. This role also included collaborating with government relations, public relations, and investor relations. Dr. Stanton also held the position of Vice President, Advanced Product Development from 2002-2005. This entailed leading a large product development team for pacemakers and defibrillators.

Marshall served for three years as a member of the Center for Medicare and Medicaid Services’ (CMS) Medicare Coverage Advisory Committee.

Before joining Medtronic, Dr. Stanton was Associate Professor of Medicine and Director of the Cardiovascular Training Program at the Mayo Graduate School of Medicine, Mayo Clinic, Rochester, Minnesota, where he was on staff from 1989 – 1998. Prior to that, he was a fellow in cardiology and electrophysiology at Indiana University School of Medicine and a Mayo Scholar. He received his Doctor of Medicine degree from the Medical College of Virginia in 1982, having received a Bachelor of Arts from the University of Pennsylvania in 1978.


Martin J. Madden

JaafarMartin J. Madden has a deep and broad background in Medical Device Innovation and New Product Development. He is a noted innovator, a leader of technology, and a leader of leaders. His passion is to bring exceptional new products and technologies to the market; and to enable engineers, scientists and leaders to thrive and realize their fullest potential.

During his thirty year tenure with Johnson & Johnson’s Medical Device organization, Martin was an innovator and research leader for nearly every medical device business including Cardiology, Electrophysiology, Peripheral Vascular Surgery, General and Colorectal Surgery, Aesthetics, Orthopaedics, Sports Medicine, Spine, and Trauma. During his tenure, thousands of products were launched, scores of leaders developed, and millions upon millions of patients treated. As an Executive and a Vice-President of Johnson & Johnson, Martin served on the management boards of Johnson & Johnson’s Global Surgery Group, Ethicon, Ethicon Endo-Surgery, DePuy-Synthes, and Cordis, with responsibility for research and development – inclusive of organic and licensed/acquired technology. Martin was also Chairman of J&J’s Medical Device Research Council, with responsibility for talent strategy and technology acceleration. Earlier in his career, Martin was a medical device engineer and innovator, and a leader of cross-functional teams charged with incubating, developing, and launching new products.

Martin’s leadership experiences spanned internal start-ups, executing turn-around’s, and leading large portfolio and technology intensive research organizations with annual investments exceeding $1 Billion. Additionally, among the numerous L&A deals and integrations, the most notable have been Biosense, Synthes, Omrix Biopharmaceuticals, and Ultracision.

Martin graduated with honors from Columbia University’s MBA program (#1 in class) and an honors graduate from Carnegie-Mellon University (Master’s degree in Mechanical Engineering), and a Summa cum Laude graduate from the University of Dayton (Bachelor’s degree in Mechanical Engineering). Martin is a past member of the University of Dayton’s School of Engineering Advisory Council.

Martin currently serves on the Board of Directors of NovoCure Limited (NVCR) and Microbot Medical Inc. (MBOT).


Andrew Betts

BettsAndy Betts is a retired audit partner from Ernst & Young where he spent thirty seven years serving publicly and privately held companies in the manufacturing, technology, financial services and insurance industries.  Andy has extensive experience in Securities and Exchange Commission reporting and in working with mergers and acquisitions.  He served as Director of Audit for the Raleigh office managing staff resources and client assignments for a professional staff of over 100.  Andy also worked on a National task force to innovate audit services to clients through technology and other audit tools.  He currently serves as a consultant on accounting matters and works part time as an audit director for BDO, USA in Raleigh.

Andy is on the board of Builders Mutual Insurance Company where he serves on the audit and governance committees.  He also is on the board of Athene Annuity and Life Assurance Company where he serves on the audit committee.  He serves on a number of local community and civic organizations and is currently board chair of StepUp Ministry.

Andy is a graduate of the University of North Carolina at Chapel Hill and the Executive Program of the Kellogg Graduate School at Northwestern University. He is a Certified Public Accountant, a member of the American Institute of CPAs and the NC Association of CPAs, a Fellow of the Life Management Institute and a Chartered Life Underwriter.


Ramesh Alur

Ramesh is a General Partner at Ventureast Fund Advisors India and has been on Mardil’s Board since 2007. He focuses on Life Science, Healthcare, and Clean Environment investments at the firm. He has been with Ventureast for over 15 years, and was part of the APIDC team prior to its partnership with Ventureast where he served as General Partner of APIDC Fund and Biotechnology Venture Fund. He has worked closely with over 50 early to growth-stage companies in pharmaceuticals, specialty chemicals, manufacturing, infrastructure services, healthcare, dairy products, and alternative fuels. He started his career in 1978 as a Chemical Engineer with Bhabha Atomic Research Center. He also worked as Scientific Officer at Reactor Research Center, Kalpakkam and served at Bakelite Hylam. He is a Director for 10 companies, which include portfolio companies as well as a group companies of Ventureast. He holds an M.B.A. in Marketing and Finance from the Indian Institute of Management, Bangalore and B.Tech. degree in Chemical Engineering from REC Warangal.


Naser Jaafar

JaafarNaser is the Executive Vice President of Strategic Initiatives and Funding at Agensi Inovasi Malaysia (AIM). His team is responsible for creating wealth through innovation for the country via three delivery channels specifically, open bidding of new technology sourced from local universities and Public Research Institutes, direct equity investment by AIM and also matching of Entrepreneurs and Promoters. Naser also heads the team at AIM, which is the joint secretariat with Ministry of Science, Technology and Innovation for the Investment Committee of Public Funds (ICPF). This team is responsible for the evaluation, development of KPIs and Performance Management of all the public funds for Research, Development and Commercialization (R,D&C) in Malaysia. Prior to joining AIM, Naser was with Bank of America Merrill Lynch Malaysia for 22 years, of which the last 9 years as the Chief Executive Officer. Naser has served various positions at the Bank in Malaysia, Singapore and Jakarta. Naser received his Masters of Business Administration from North Texas State University, USA in 1987.